3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
11
Sarcoma
6
Neoplasms
6
Lymphoma, Mantle-Cell
6
Prostatic Neoplasms
5
Lymphoma, Non-Hodgkin
5
Rhabdomyosarcoma
4
Neoplasm Metastasis
4
Kidney Neoplasms
4
Gliosarcoma
4
Glioblastoma
4
Breast Neoplasms
4
Brain Neoplasms
4
Waldenstrom Macroglobulinemia
3
Osteosarcoma
3
Melanoma
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Endometrial Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Liposarcoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Glioma
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
temsirolimus
×
Clear all
No trials found.